In clinical practice, monoclonal antibodies blocking either IL‐17A or its receptor have been confirmed to be the first‐line treatment for moderate‐to‐severe plaque psoriasis (the clinical PASI score> 10) [27]. The gene discussed is IL17A; the disease is psoriasis vulgaris.